Journal of Pharmacological and Toxicological Methods 2014-01-01

Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats.

Shinji Kobuchi, Yukako Ito, Taro Hayakawa, Asako Nishimura, Nobuhito Shibata, Kanji Takada, Toshiyuki Sakaeda

Index: J. Pharmacol. Toxicol. Methods 70(2) , 134-44, (2014)

Full Text: HTML

Abstract

The aim of the present study was to develop a simple pharmacokinetic-pharmacodynamic (PK-PD) model in rats that could predict the onset and degree of erythropenia, a severely toxic side effect that severely limits the use of the anticancer agent 5-fluorouracil (5-FU).Total erythrocyte counts, hemoglobin (Hb) concentrations, and hematocrit (Hct) levels were measured in rats following the intravenous bolus administration of 5-FU for 4 days in order to obtain data for an analysis of the PK-PD model. Our PK-PD model consisted of a two-compartment PK model, with two compartments for the PD model and nine structural PK-PD model parameters.After the intravenous bolus administration of 5, 10, or 20 mg/kg of 5-FU to rats, absolute erythrocyte counts, Hb concentrations, and Hct levels transiently decreased, reached minimum levels on Days 7-14, and then returned to baseline levels. The nadir values (Cnadir) for rats treated with 5, 10, or 20 mg/kg of 5-FU were significantly decreased to approximately 79.4, 76.3, or 46.5% of the baseline value (Cbaseline) in erythrocyte counts, 86.3, 83.3, or 45.7% of Cbaseline in Hb concentrations, 88.6, 85.5, or 47.1% of Cbaseline in Hct levels, respectively. The PK-PD model effectively captured the features of erythropenia and Cnadir after 5-FU chemotherapy. This PK-PD model was successfully used to characterize the learner relationship between the area under the plasma 5-FU concentration-time curve (AUC0-∞) following the intravenous bolus administration of 5-FU and the Cnadir in erythrocyte counts, Hb concentrations, and Hct levels after the 5-FU treatment.The results of the present study suggest that the administration of a pharmacokinetically modified dose of 5-FU could minimize the Cnadir in erythrocyte counts, Hb concentrations, and Hct levels following the administration of 5-FU. The PK-PD model and simulation represent valuable approaches for quantifying and predicting erythropenia as well as determining individual doses and the time at which the subsequent course of the treatment should start.Copyright © 2013 Elsevier Inc. All rights reserved.


Related Compounds

Related Articles:

TAp73 promotes cell survival upon genotoxic stress by inhibiting p53 activity.

2014-09-30

[Oncotarget 5(18) , 8107-22, (2014)]

cIEF for rapid pKa determination of small molecules: a proof of concept.

2014-10-15

[Eur. J. Pharm. Sci. 63 , 14-21, (2014)]

Establishment and characterization of cell lines from chromosomal instable colorectal cancer.

2015-01-07

[World J. Gastroenterol. 21(1) , 164-76, (2015)]

Targeted Delivery of 5-fluorouracil with Monoclonal Antibody Modified Bovine Serum Albumin Nanoparticles.

[Iran. J. Pharm. Res. 14(2) , 395-405, (2015)]

Atonal homolog 1 protein stabilized by tumor necrosis factor α induces high malignant potential in colon cancer cell line.

2015-08-01

[Cancer Sci. 106 , 1000-7, (2015)]

More Articles...